Parenteral drugs market value to be worth $802 billion by 2029, says study

24 January 2020

2019_biotech_test_diagnostic_injection_big

The parenteral drugs market – which was worth an estimated $451 billion in 2019 – will be worth $802 billion in 2029, according to a Fact.MR study.

Rising prevalence of chronic illnesses such as cancer, cardiovascular diseases and diabetes across the globe, has been the prime revenue driver for parenteral drugs and this trend is not likely to abate any time in the foreseeable future, the study finds.

By product type, the monoclonal antibodies segment is found to account for maximum market share in terms of revenue in this market, something that is primarily attributed to the rising adoption of biologics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK